MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
6.62
+0.22
+3.44%
After Hours: 6.64 +0.02 +0.31% 16:38 11/11 EST
OPEN
6.47
PREV CLOSE
6.40
HIGH
6.72
LOW
6.43
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
31.35
52 WEEK LOW
4.585
MARKET CAP
856.86M
P/E (TTM)
-1.7379
1D
5D
1M
3M
1Y
5Y
1D
ALMS Now Depends on Whether Regulatory Conviction Matches Management Confidence After That Lupus Miss
Barchart · 15h ago
Weekly Report: what happened at ALMS last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at ALMS last week (1026-1030)?
Weekly Report · 11/02 09:18
Alumis Caps Key Psoriasis Trial, Raising Stakes for ALMS Investors
TipRanks · 10/28 16:30
Alumis’ Phase 3 Psoriasis Trial Reaches Completion, Raising the Stakes for ALMS Investors
TipRanks · 10/28 16:30
Weekly Report: what happened at ALMS last week (1019-1023)?
Weekly Report · 10/26 09:18
Weekly Report: what happened at ALMS last week (1012-1016)?
Weekly Report · 10/19 09:18
Weekly Report: what happened at ALMS last week (1005-1009)?
Weekly Report · 10/12 09:19
More
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.